ICYMI: PR Newswire has rolled out a free, fully customizable #healthcare focused newsfeed. The newsfeed will feature releases on your site, not redirect traffic. Learn more here: prn.to/2ZGzwsD #health #content

Zydus announces agreement with CVS Caremark to add Zituvio™, Zituvimet™ and Zituvimet™ XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) to its template formulary prnewswire.com/news-releases…

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment prnewswire.com/news-releases…

$RDHL awarded $8 million plus costs in New York Supreme Court summary judgment against Kukbo. #RDHL prnewswire.com/il/news-relea…

Meril Champions Innovation with Myval Octapro THV Launch at GISE 2024 & PCR LondonValves 2024 prnewswire.co.uk/news-releas…

New Ipsos global survey shines a light on the myopia epidemic prnewswire.co.uk/news-releas…

#RDHL & @DukeMedSchool to develop #opaganib as a medical #countermeasure for phosgene injury, aimed toward advanced U.S. government-sponsored #FDA Animal Rule development. $RDHL PR: prnewswire.com/il/news-relea…

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries prnewswire.com/news-releases…

#RDHL #opaganib granted new @USPTO patent for identification of a novel biomarker of coronavirus pneumonia - prognostic for potential opaganib efficacy in treating COVID-19, valid through 2041. $RDHL PR: prnewswire.com/news-releases…

Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US prnewswire.com/news-releases…

#RDHL’s #Talicia, positioned first-line for the treatment of # HPylori infection in the new @AmCollegeGastro clinical guideline. Read the $RDHL PR: prnewswire.com/news-releases…

Exciting Developments in Clinical Research: Axcellant's Groundbreaking Global Study prnewswire.com/news-releases…

#RDHL #opaganib granted @US_FDA #orphandrug status for #neuroblastoma, the most common #infant #malignancy accounting for 15% of #pediatric #cancer deaths. Broad #oncology potential & 7-years exclusivity. $RDHL PR: bit.ly/3XjmboE #FDA

New publication in @antibioticsmdpi of ground-breaking positive data from #RDHL’s Phase 3 Crohn’s study shows #RHB-104 + standard of care (SoC) was 64% more effective than SoC alone. Primary endpoint met with high statistical significance $RDHL PR: bit.ly/3SwGn3U#Antibiotics

YewMaker - New Playbook Launches to Tackle Global Challenge of Wasted Medicines prnewswire.com/news-releases…

$RDHL 2023 results: “RedHill is transformed - focused on predominantly U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base & unburdened by debt, with a clear value proposition”. #RDHL PR: prnewswire.com/news-releases…

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price prnewswire.com/news-releases…

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 prnewswire.com/news-releases…

Response Plus Medical announces strategic acquisition of UK-based Prometheus as part of global expansion plans prnewswire.co.uk/news-releas…

Oxford Medical Simulation Raises $12.6 Million in Series A Funding to Address Critical Healthcare Training Gap with Virtual Reality prnewswire.com/news-releases…

JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis prnewswire.com/news-releases…